The Latest Breaking News from Johnson & Johnson (

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year

Cork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on the sector

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Markets are getting into the freewheeling rhythm of a second Trump administration.

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Despite a relentless market-wide selloff on Friday, Coca-Cola, Johnson & Johnson, and McDonald’s showed notable strength, defying the broader downtrend.

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in the economic and geopolitical spheres. In this volatile environment, investors may find value in fundamentally stable stocks like Microsoft (MSFT), Alphabet (GOOGL), and Johnson & Johnson (JNJ). Continue to read….

Group action with 3,500 claimants alleges company knew its talcum powder products contained dangerous asbestos